TCG Crossover (TCGX) is a healthcare and life sciences investment firm dedicated to advancing disruptive medicines. It invests across both private and public markets, focusing on innovative biotech companies building transformative therapies.
39% of their portfolio is in Biotech & Life Sciences. They made 4 investments in the last 12 months. Their most common stage is series-b (56% of deals). Average disclosed round size is $164.8M (across 18 rounds with reported amounts).
Portfolio
16
Fund Size
$1.3B
Top Stage
Series B
Last 12 Mo
4
Team
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
18 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| CCorxel | Series D | $287M | Sep 2026 |
| AAccro | Series C | $50M | May 2026 |
| CCorxel Pharmaceuticals Limited | Series D | $287M | Jan 2026 |
| CCorxel | Series D | $287M | Jan 2026 |
 Vicebio | Series B | $100M | Sep 2024 |
| PPathalys Pharma | Series B | $105M | Aug 2024 |
 Pheon Therapeutics | Series B | $120M | May 2024 |
| UUpstream Bio, Inc. | Series B | $200M | Jun 2023 |
 Plexium | Growth | $102M | Feb 2022 |
 Arbor Biotechnologies | Series B | $215M | Nov 2021 |
| AArtios Pharma Limited | Series C | $153M | Jul 2021 |
 Entrada Therapeutics | Series B | $116M | Mar 2021 |
 Entrada | Series B | $116M | Jan 2021 |
 Arbor Biotechnologies | Series B | $215M | Jan 2021 |
 RayzeBio | Series C | $108M | Jan 2021 |
| SSynthekine, Inc. | Series B | $107.5M | — |
| CCorxel Pharmaceuticals Limited | Unknown | $287M | — |
| AAffinia Therapeutics | Series B | $110M | — |
Top Co-Investors
RA Capital Management8 shared
HBM Healthcare Investments5 shared
Samsara BioCapital4 shared
SR One4 shared
SymBiosis4 shared
OrbiMed3 shared
Wellington Management3 shared
The Goldman Sachs Group, Inc.3 shared
Redmile Group3 shared
Omega Funds3 shared
The Invus Group, LLC3 shared
Deep Track Capital3 shared
Logos Capital3 shared
Surveyor Capital3 shared
Perceptive Advisors3 shared
LAV2 shared
MRL Ventures Fund2 shared
Greenspring Associates2 shared
Roche Venture Fund2 shared
Last updated: 20 October 2026